Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


InnoCentive LLC

Division of Eli Lilly & Co.

Latest From InnoCentive LLC

People Power: How The Crowd May Shape The Funding And Development Of Drugs

Companies are sprouting across the pharma value chain that harness the voices of patients and other individual stakeholders to drive the research, development, and financing of drugs. Pharma is taking tentative steps toward using these methods, but high barriers remain to their systematic integration in R&D.

BioPharmaceutical Innovation

Armed With An FDA-Cleared IND, TLS Sets Out To Democratize Clinical Trials

Transparency Life Sciences applies crowdsourcing to the design of clinical protocols with the aim of lowering costs and improving outcomes for clinical trials. The company won FDA clearance for its first IND based on a protocol that resulted from its process and is securing its first financing.

BioPharmaceutical Strategy

Corporate Venture Capital's Complex Agenda

Several forces--rapid technological obsolescence, the impact of information technology on health care, merger integrations, and the need for double digit revenue growth--have caused increasing numbers of large pharmaceutical and medical device companies to create new corporate venture capital groups. But compared to traditional VC firms, whose only goal is to make money for limited partners, corporate VCs have a heavy agenda. They must choose portfolio companies while balancing often-competing goals of strategic benefit and financial return.
BioPharmaceutical Medical Device

Lilly's Web-Based Research Marketplace

Eli Lilly & Co. is venturing into previously uncharted e-R&D waters with Innocentive LLC, a wholly owned subsidiary launched earlier this summer with an undisclosed amount of backing. Innocentive offers a means for pharmaceutical and other research-dependent companies to farm out research problems to scientists who receive cash awards of up to $100,000 from any company that accepts a particular solution.
BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Digital Health
  • Therapeutic Areas
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Eli Lilly & Co.
  • Senior Management
  • Darren Carroll, CEO
    Alpheus Bingham, PhD, Chmn.
    Thomas Venable, EVP, Sales & Mktg.
  • Contact Info
  • InnoCentive LLC
    Phone: (866) 812-7339
    Indianapolis, IN